eye drops delay, will prevent, myopia

Published Date: 16 Feb 2023

Researchers have found that dilating eye drops that children use daily can delay the onset of myopia.

Read Full News

Latest News

Dry Eye Drug Does Well in Study, but FDA Remains Unconvinced

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Sarcoid Uveitis: 1 in 3 Achieve Remission, Relapses Rare

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Female Eye Doctors Earn Less Across All Ranks

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Todays Updates

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

GuCS: Genitourinary Cancers Symposium

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

Todays Updates

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

GuCS: Genitourinary Cancers Symposium

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

Latest News

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

News All Time

Metabolic Syndrome Tied to Glaucoma Risk

Metabolic syndrome, rather than BMI or waist circumference, is linked to an increased likelihood of glaucoma and may better identify adults who could benefit from closer eye screening.

Two Biologics Show Comparable Benefit in Uveitis

Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.

Ocular Therapeutix Plunges as Modest Benefit Overshadow Trial Win Over Regeneron's Eylea

Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but ⁠its modest advantage and higher rates of certain side...

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Recommended News For You

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

Medicaid expansion tied to smaller declines in early-stage cancer detection

Updates from the 2022 WHO classification of kidney epithelial tumors

A paper strip test might enable the early detection of cancer.

Report reveals lung cancer is the leading cause of cancer deaths in Florida

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

Immunotherapy and targeted radiation shrink liver tumors, enabling surgery

Recommended Articles For You

Uncovering the Causes of Thrombocytosis: A Journey to Improved Health 

Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact 

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review 

What Is Degos Disease? A Comprehensive Overview Of Symptoms, Diagnosis, and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.

2.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

3.

Significant worldwide disparities seen in availability and timeliness of new cancer drugs

4.

CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group

5.

Report reveals lung cancer is the leading cause of cancer deaths in Florida

1.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

2.

Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment

3.

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?

4.

Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options

5.

A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

4.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

5.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot